Standout Papers

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, co... 2019 2026 2021 2023 746
  1. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial (2019)
    Richard Furie, Eric F. Morand et al. The Lancet Rheumatology
  2. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis (2022)
    David Jayne, Brad H. Rovin et al. Annals of the Rheumatic Diseases
  3. Trial of Anifrolumab in Active Systemic Lupus Erythematosus (2019)
    Eric F. Morand, Richard Furie et al. New England Journal of Medicine

Immediate Impact

3 from Science/Nature 56 standout
Sub-graph 1 of 21

Citing Papers

Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics
2025 Standout
Self-Cascaded Pyroptosis-STING Initiators for Catalytic Metalloimmunotherapy
2025 Standout
20 intermediate papers

Works of Raj Tummala being referenced

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
2022 Standout
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
2019 Standout
and 23 more

Author Peers

Author Last Decade Papers Cites
Raj Tummala 1833 842 1331 77 2.6k
Zahi Touma 2936 743 1952 175 3.9k
Amy Kao 1865 451 1399 90 3.2k
Alberta Hoi 1735 414 1601 76 2.5k
P. C. Limburg 1253 412 1249 52 3.6k
Bridget Griffiths 2215 580 1264 70 3.3k
Won Park 1314 392 1834 88 3.0k
Inmaculada del Rincón 2690 266 757 45 3.8k
Antonio Manzo 1300 394 1146 70 2.9k
Swapan K. Nath 1595 501 1857 102 3.8k
Meggan Mackay 1859 684 1668 51 3.1k

All Works

Loading papers...

Rankless by CCL
2026